Psilocybin (Magic Mushrooms) | National Institute on Drug Abuse Psilocin activity at the 5HT2a receptor affects how the brain works and how different brain regions communicate with each other These altered patterns of brain activity contribute to a person’s profound change in consciousness
La psilocibina (setas u hongos mágicos) - National Institute on Drug . . . Cuando una persona toma psilocibina, su cuerpo la convierte en otra sustancia, la psilocina La psilocina se une y activa los receptores, o sitios de unión, para la serotonina química del cerebro, principalmente el receptor de serotonina 5-hidroxitriptamina 2A (5HT2a)
Law enforcement seizures of psilocybin mushrooms rose dramatically . . . Law enforcement seizures of “magic mushrooms” or “shrooms” containing the psychoactive component psilocybin increased dramatically in the United States between January 2017 and December 2022, according to a new study funded by the National Institute on Drug Abuse, part of the National Institutes of Health
Psychedelic and Dissociative Drugs | National Institute on Drug Abuse Psychedelic and dissociative drugs can temporarily alter a person’s mood, thoughts, and perceptions of reality 1 Among other health effects and safety concerns, people who use psychedelic and dissociative drugs report feeling strong emotions, ranging from intense happiness and a feeling of connectedness to fear, anxiety, and confusion 2,3 People who use these drugs also report experiencing
Xylazine | National Institute on Drug Abuse (NIDA) Xylazine is a tranquilizer, pain reliever, and central nervous system depressant that is U S Food and Drug Administration (FDA)-approved for use in veterinary medicine
NIDA IRP - Michael Baumann, Ph. D. Background Michael H Baumann, PhD, is a Staff Scientist and Facility Head at the National Institute on Drug Abuse, Intramural Research Program, in Baltimore, MD Dr Baumann joined NIDA in 1991 as a Staff Fellow in the laboratory of Richard B Rothman, MD, PhD
National Institute on Drug Abuse RESEARCH RESEARCHNational Institute on Drug Abuse MONOGRAPH SERIES Hallucinogens: An Update 146 U S Department of Health and Human Services • Public Health Service • National Institutes of Health